Mogrify
Mogrify is a biotechnology company that develops proprietary tailored cell conversions that power every cell therapy.
Mogrify has raised €38M across 3 funding rounds from 7 investors, most recently a Series A round in Oct 2023. Based in Cambridge, UK; founded 2016; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€38M
€38,375,522
Funding rounds
3
Investors
7
distinct backers
Active since
2019-10
latest 2023-10
Funding by year
EUR raised per yearMogrify — funding by year — interactive chart.
Data table
| Mogrify — funding by year | |
|---|---|
| 2019 | €15M |
| 2021 | €14M |
| 2023 | €9.6M |
Signals
High confidenceRaise-next likelihood10
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 10y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-10-03 | Series A | €9.6M | Ahren Innovation Capital,Astellas Venture Management,Dr Jonathan Milner,Parkwalk Advisors,Trend Investment Group | View deal → |
| 2021-05-04 | Series A | €14M | 24Haymarket,Astellas Venture Management,Dr Darrin M Disley,Dr Jonathan Milner,Parkwalk Advisors | View deal → |
| 2019-10-01 | Series A | €15M | Ahren Innovation Capital | View deal → |